Devi J Sakthi Usha, T D Balamurugan, Rao H Prasanna Srinivasa, Kumar A Ajay
Present Address: Department of Surgical Oncology, Govt Arignar Anna Memorial Cancer Hospital and Research Institute - Regional Cancer Centre, Karapettai, Kanchipuram, Tamil Nadu 631552 India.
Indian J Surg Oncol. 2025 Apr;16(2):456-464. doi: 10.1007/s13193-023-01762-4. Epub 2023 May 10.
The early diagnosis and aggressive treatment in patients diagnosed with a cancer led them to lead a life with a good survival rate. This in turn leads to increase in the number of second primary malignancies. Our article aims to report the prevalence and survival of both synchronous and metachronous second primary malignancies and challenges in treatment by reviewing our retrospective data. A hospital based gathering of retrospective data of the patients diagnosed with second primary malignancies over 9 years from January 2014 to June 2022. Patient details with regards to age, sex, distribution of primary sites, histopathology reports, synchronous or metachronous, treatment details are recorded (Patients fulfilling IARC Definition and Warren Gates criteria). A total of 86 patients were analysed in the retrospective data of whom females contribute the most - 74.4% ( = 64). Metachronous type of tumours - 68.6% ( = 59) are common than synchronous tumours. Overall, patients with breast cancer are more vulnerable for second primary malignancies accounting for 31% and second primary were prone to occur in the ovary followed by cervix. The median survival following first primary tumour diagnosis was 44 months and that of the second primary tumour was 11 months. With advanced screening procedures and evolving treatments, the incidence of second primary malignancies is steadily increasing and the outcomes are poorer since there are no proper set guidelines. More awareness, research and studies are needed to investigate in the treatment of second primary malignancies.
对癌症患者进行早期诊断和积极治疗，可使他们过上存活率较高的生活。这反过来又导致了第二原发性恶性肿瘤数量的增加。我们的文章旨在通过回顾我们的回顾性数据，报告同时性和异时性第二原发性恶性肿瘤的患病率、生存率以及治疗中的挑战。这是一项基于医院的回顾性数据收集研究，收集了2014年1月至2022年6月期间9年内被诊断为第二原发性恶性肿瘤的患者的数据。记录患者的年龄、性别、原发部位分布、组织病理学报告、同时性或异时性、治疗细节等信息（符合国际癌症研究机构定义和沃伦·盖茨标准的患者）。在回顾性数据中，共分析了86例患者，其中女性占比最高，为74.4%（n = 64）。异时性肿瘤类型占68.6%（n = 59），比同时性肿瘤更为常见。总体而言，乳腺癌患者更容易发生第二原发性恶性肿瘤，占31%，第二原发性肿瘤容易发生在卵巢，其次是子宫颈。首次原发性肿瘤诊断后的中位生存期为44个月，第二次原发性肿瘤的中位生存期为11个月。随着先进筛查程序和治疗方法的不断发展，第二原发性恶性肿瘤的发病率在稳步上升，而且由于没有适当的既定指南，治疗结果较差。需要提高更多认识、开展更多研究来调查第二原发性恶性肿瘤的治疗方法。
